NO20025307L - Anvendelse av IL-18 inhibitorer til behandling og/eller forebygging av aterosklerose - Google Patents

Anvendelse av IL-18 inhibitorer til behandling og/eller forebygging av aterosklerose

Info

Publication number
NO20025307L
NO20025307L NO20025307A NO20025307A NO20025307L NO 20025307 L NO20025307 L NO 20025307L NO 20025307 A NO20025307 A NO 20025307A NO 20025307 A NO20025307 A NO 20025307A NO 20025307 L NO20025307 L NO 20025307L
Authority
NO
Norway
Prior art keywords
atherosclerosis
inhibitors
prevention
treatment
Prior art date
Application number
NO20025307A
Other languages
English (en)
Other versions
NO329821B1 (no
NO20025307D0 (no
Inventor
Yolande Chvatchko
Ziad Mallat
Alain Tedgui
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of NO20025307D0 publication Critical patent/NO20025307D0/no
Publication of NO20025307L publication Critical patent/NO20025307L/no
Publication of NO329821B1 publication Critical patent/NO329821B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20025307A 2000-05-05 2002-11-05 Anvendelse av IL-18 inhibitorer, ekspresjonsvektorer som koder for IL-18 inhibitorer og celler genetisk modifisert til a fremstille inhibitorer av IL-18 for fremstilling av medikamenter til behandling og/eller forebygging av aterosklerose, samt anvendelse av IL-18 som diagnostisk markor for progresjon av aterosklerose NO329821B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05
PCT/EP2001/004843 WO2001085201A2 (en) 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

Publications (3)

Publication Number Publication Date
NO20025307D0 NO20025307D0 (no) 2002-11-05
NO20025307L true NO20025307L (no) 2002-12-18
NO329821B1 NO329821B1 (no) 2010-12-27

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025307A NO329821B1 (no) 2000-05-05 2002-11-05 Anvendelse av IL-18 inhibitorer, ekspresjonsvektorer som koder for IL-18 inhibitorer og celler genetisk modifisert til a fremstille inhibitorer av IL-18 for fremstilling av medikamenter til behandling og/eller forebygging av aterosklerose, samt anvendelse av IL-18 som diagnostisk markor for progresjon av aterosklerose

Country Status (32)

Country Link
US (1) US20040076628A1 (no)
EP (1) EP1278540B1 (no)
JP (1) JP5122053B2 (no)
KR (2) KR100798545B1 (no)
CN (2) CN1250286C (no)
AR (1) AR035640A1 (no)
AT (1) ATE395075T1 (no)
AU (2) AU6739001A (no)
BG (1) BG65881B1 (no)
BR (1) BRPI0110506B8 (no)
CA (1) CA2407895C (no)
CY (1) CY1110385T1 (no)
CZ (1) CZ300792B6 (no)
DE (1) DE60134009D1 (no)
DK (1) DK1278540T3 (no)
EA (2) EA007014B1 (no)
EE (1) EE05056B1 (no)
ES (1) ES2305082T3 (no)
HR (1) HRP20020828A2 (no)
HU (1) HU229375B1 (no)
IL (2) IL152567A0 (no)
ME (1) ME00554B (no)
MX (1) MXPA02010895A (no)
NO (1) NO329821B1 (no)
PL (1) PL209371B1 (no)
PT (1) PT1278540E (no)
RS (1) RS50926B (no)
SI (1) SI1278540T1 (no)
SK (1) SK287761B6 (no)
UA (2) UA87658C2 (no)
WO (1) WO2001085201A2 (no)
ZA (1) ZA200208228B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
CN1326562C (zh) * 2001-01-29 2007-07-18 应用研究系统Ars股份公司 Il－18抑制剂制造治疗和/或预防心脏病的药物的应用
HRP20030842B1 (hr) 2001-05-25 2017-06-02 Ares Trading S.A. UPOTREBA IL-18 INHIBITORA ZA LIJEČENJE I PREVENCIJU OZLJEDA CNS-a
US6797727B2 (en) * 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
BRPI0308663B8 (pt) * 2002-03-22 2021-05-25 Applied Res Systems Ars Holding N V uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
US7824907B2 (en) * 2003-03-11 2010-11-02 Merck Serono Sa Expression vectors comprising the mCMV IE2 promoter
US20080076708A1 (en) 2003-05-13 2008-03-27 Valter Altarocca Active Variants of the Il-18 Binding Protein and Medical Uses Thereof
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
DK1755642T3 (da) * 2004-04-15 2010-05-10 Athera Biotechnologies Ab Annexin V til forebyggelse af plaksprængning
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
AU2006254103B2 (en) 2005-06-03 2012-09-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
AU2006256763B2 (en) 2005-06-10 2012-08-02 Ares Trading S.A. Process for the purification of IL-18 binding protein
KR101603001B1 (ko) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
UA125204C2 (uk) 2013-09-05 2022-02-02 Аб2 Біо Са Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질

Also Published As

Publication number Publication date
HU229375B1 (en) 2013-11-28
AU2001267390B2 (en) 2005-09-22
ATE395075T1 (de) 2008-05-15
MEP64008A (en) 2011-12-20
PT1278540E (pt) 2008-07-03
EP1278540A2 (en) 2003-01-29
JP2003532685A (ja) 2003-11-05
SI1278540T1 (sl) 2008-10-31
PL209371B1 (pl) 2011-08-31
PL365697A1 (en) 2005-01-10
CZ20023644A3 (cs) 2003-03-12
CN1434722A (zh) 2003-08-06
CN1841066A (zh) 2006-10-04
IL152567A0 (en) 2003-05-29
AR035640A1 (es) 2004-06-23
EE200200620A (et) 2004-06-15
CA2407895C (en) 2012-12-18
CN1841066B (zh) 2012-08-29
UA78492C2 (en) 2007-04-10
CN1250286C (zh) 2006-04-12
BG65881B1 (bg) 2010-04-30
KR100798545B1 (ko) 2008-01-28
KR20030016254A (ko) 2003-02-26
EP1278540B1 (en) 2008-05-14
CA2407895A1 (en) 2001-11-15
SK15562002A3 (sk) 2003-05-02
EA007014B1 (ru) 2006-06-30
HUP0301991A3 (en) 2006-11-28
HK1055681A1 (en) 2004-01-21
RS50926B (sr) 2010-08-31
KR20070073989A (ko) 2007-07-10
NO329821B1 (no) 2010-12-27
BRPI0110506B8 (pt) 2021-05-25
DK1278540T3 (da) 2008-07-21
HUP0301991A2 (hu) 2003-09-29
EA200201175A1 (ru) 2003-04-24
CY1110385T1 (el) 2015-04-29
DE60134009D1 (de) 2008-06-26
EA005410B1 (ru) 2005-02-24
HK1094909A1 (en) 2007-04-13
MXPA02010895A (es) 2003-03-27
UA87658C2 (uk) 2009-08-10
HRP20020828A2 (en) 2004-12-31
WO2001085201A3 (en) 2002-05-10
ES2305082T3 (es) 2008-11-01
IL152567A (en) 2010-12-30
WO2001085201A2 (en) 2001-11-15
BRPI0110506B1 (pt) 2015-05-19
EA200401183A1 (ru) 2004-12-30
ME00554B (me) 2012-03-20
YU82602A (sh) 2006-01-16
EE05056B1 (et) 2008-08-15
SK287761B6 (en) 2011-09-05
US20040076628A1 (en) 2004-04-22
JP5122053B2 (ja) 2013-01-16
NO20025307D0 (no) 2002-11-05
ZA200208228B (en) 2005-07-27
CZ300792B6 (cs) 2009-08-12
BG107218A (bg) 2003-06-30
BR0110506A (pt) 2003-04-01
AU6739001A (en) 2001-11-20

Similar Documents

Publication Publication Date Title
NO20025307L (no) Anvendelse av IL-18 inhibitorer til behandling og/eller forebygging av aterosklerose
NO20044195L (no) Biofosfoninsyrer for behandling og prevensjon av osteoprose
NO20032668D0 (no) Gyraseinhibitorer og anvendelser derav
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
DK1251848T3 (da) Gyraseinhibitorer og anvendelse deraf
NO20024610L (no) Synergistiske metoder og blandinger for behandling av kreft
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
IS6700A (is) Meðferðarblanda CETP hindra og atórvastatíns
NO20015274L (no) ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
EP1196158A4 (en) INHIBITION OF ANGIOGENESIS THROUGH THE USE OF CURCUMIN AND CURCUMINOIDS
NO20022656D0 (no) Caspaseinhibitorer og anvendelse derav
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20021587D0 (no) Sementeringsblandinger og bruk av slike blandinger for sementering av brönner eller lignende
NO20041004L (no) Fremgangsmate og anordning for sammensetting av gjenfestbare absorberende klesplagg
NO20031806D0 (no) Anvendelse av pericytt apoptosehemmere for behandling og/eller forhindringav diabetisk retinopati
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20015772L (no) Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom
NO20033228D0 (no) Anvendelse av IL-18 inhibitorer til behandling og/eller forhindring av hjertesykdom
PT1274700E (pt) Di-hidrobenzopiranos di-hidrobenzotiopiranos e tetra-hidroquinolinas para o tratamento de afeccoes mediadas por cox-2
NO20023737D0 (no) Fremgangsmåte og preparater for behandling av en inflammatorisk lidelse
EE05263B1 (et) IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
NO20035299D0 (no) Preparater og syklooksygenase-2-selektive inhibitorer og bestråling for inhibering eller forhindring av kardiovaskul¶re sykdommer
DK1307761T3 (da) Fremgangsmåde til retningsbestemmelse og bestemmelsesapparat
NO20040177L (no) Karbamatforbindelser for bruk til forebyggelse eller behandling av neuropatisk smerte og kluster- og migrenehodepineassosiert smerte

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

MK1K Patent expired